Nxera Pharma Receives $15 Million Milestone Payment as Phase 3 Schizophrenia Trial Begins

Sosei Group ( (JP:4565) ) has provided an update.

Nxera Pharma announced that its partner, Neurocrine Biosciences, has initiated the Phase 3 trial of NBI-1117568 for schizophrenia, resulting in a $15 million payment to Nxera. This milestone reflects Nxera’s strategic partnerships and its focus on addressing significant unmet needs in the medical field, potentially enhancing its market positioning and stakeholder value.

The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing and commercializing innovative medicines to address unmet medical needs in Japan and globally. The company operates an agile commercial business in Japan and the broader APAC region, leveraging its NxWave™ discovery platform to advance a pipeline of over 30 active programs targeting neurology/neuropsychiatry, metabolic diseases, and immunology and inflammation. Nxera employs around 400 people across key locations worldwide and is listed on the Tokyo Stock Exchange.

YTD Price Performance: -13.36%

Average Trading Volume: 956,140

Technical Sentiment Signal: Sell

Current Market Cap: Yen82.07B

For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.